PTPN11
Tyrosine-protein phosphatase non-receptor type 11
As of the edition of 20 October 2026, PTPN11 (tyrosine-protein phosphatase non-receptor type 11, UniProt Q06124) has 9 drugs tested at it and 13 companies on the list, 4 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q06124
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- Inside the cell
- Solved structures
- 117
- Disease areas
- Cancer; Lungs and airways; Digestive system; Inherited and neonatal; Bones, joints and muscles; Heart and blood vessels; Skin and connective tissue; Hormones
- Registered trials of its drugs
- 42
Drugs at this target
| Status | Count |
|---|---|
| Active | 4 |
| Stopped | 3 |
| Status not established | 2 |
| Total | 9 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Batoprotafib | Active | Phase 2 | none listed |
| BBP-398 | Stopped | Phase 2 | none listed |
| Vociprotafib | Active | Phase 2 | none listed |
| ERAS-601 | Stopped | Phase 2 | none listed |
| JAB-3312 | Active | Phase 3 | none listed |
| Migoprotafib | Active | Phase 1 | none listed |
| JAB-3068 | Status not established | Phase 2 | none listed |
| ET0038 | Status not established | Phase 1 | none listed |
| PF-07284892 | Stopped | Phase 1 | none listed |
9 of 9 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Engaged | 7 |
| Undetermined | 2 |
| Total on the list | 13 |
The other 10 companies at PTPN11
In the product13 companies in all; 10 are not named here, and no score is.
See the 13 companies at PTPN11, ranked, with the facts behind eachRequest access. Nothing is shown until you do.